Identification of an Annonaceous Acetogenin Mimetic, AA005, as an AMPK Activator and Autophagy Inducer in Colon Cancer Cells

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Liu, Yong Qiang ^a,b   Cheng, Xin ^a   Guo, Liang Xia ^a   Mao, Chan ^c   Chen, Yi Jie ^c   Liu, Hai Xia ^c   Xiao, Qi Cai ^d   Jiang, Sheng ^d   Yao, Zhu Jun ^c   Zhou, Guang Biao ^a  

^a INSTITUTE OF ZOOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c NANJING UNIVERSITY   (China)

^d GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETOGENIN; ADENOSINE TRIPHOSPHATE; CISPLATIN; DEOXYGLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

ANNONACEAE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; CANCER CELL; CELL CYCLE ARREST; CELL PROLIFERATION; COLON CANCER; GLYCOLYSIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; RESPIRATORY CHAIN; SIGNAL TRANSDUCTION; UPREGULATION;

ACETOGENINS; ADENOSINE TRIPHOSPHATE; AMP-ACTIVATED PROTEIN KINASES; AUTOPHAGY; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; FATTY ALCOHOLS; HUMANS; LACTONES; PYRAZOLES; PYRIMIDINES;

EID: 84867313494     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047049     Document Type: Article

References (47)

1. Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, Saavedra E, (2007) Energy metabolism in tumor cells. FEBS J 274: 1393-1418.
2. Hnanhan D, Weinberg RA, (2011) Hallmarks of Cancer: The Next Generation. Cell 144: 646-674.
3. Vander Heiden MG, (2011) Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10: 671-684.
4. Hardie DG, (2011) AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev 25: 1895-1908.
5. Carling D, Mayer FV, Sanders MJ, Gamblin SJ, (2011) AMP-activated protein kinase: nature's energy sensor. Nat Chem Biol 7: 512-518.
6. Hawley SA, Davison M, Woods A, Davies SP, Beri RK, et al. (1996) Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem 271: 27879-27887.
7. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, et al. (2004) The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 101: 3329-3335.
8. Bardeesy N, Sinha M, Hezel AF, Signoretti S, Hathaway NA, et al. (2002) Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 419: 162-167.
9. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, et al. (2007) LKB1 modulates lung cancer differentiation and metastasis. Nature 448: 807-810.
10. Bolster DR, Crozier SJ, Kimball SR, Jefferson LS, (2002) AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem 277: 23977-23980.
11. Horman S, Browne G, Krause U, Patel J, Vertommen D, et al. (2002) Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol 12: 1419-1423.
12. Inoki K, Zhu T, Guan KL, (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590.
13. Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, et al. (2001) Mammalian TOR: a homeostatic ATP sensor. Science 294: 1102-1105.
14. Imamura K, Ogura T, Kishimoto A, Kaminishi M, Esumi H, (2001) Cell cycle regulation via p53 phosphorylation by a 5′-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun 287: 562-567.
15. Bowker SL, Majumdar SR, Veugelers P, Johnson JA, (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29: 254-258.
16. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD, (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305.
17. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N, (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67: 10804-10812.
18. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M, (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66: 10269-10273.
19. Ben S, I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, et al. (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27: 3576-3586.
20. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, et al. (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67: 6745-6752.
21. Tang YC, Williams BR, Siegel JJ, Amon A, (2011) Identification of Aneuploidy-Selective Antiproliferation Compounds. Cell 144: 499-512.
22. Landolt JL, Ahammadsahib KI, Hollingworth RM, Barr R, Crane FL, et al. (1995) Determination of structure-activity relationships of Annonaceous acetogenins by inhibition of oxygen uptake in rat liver mitochondria. Chem Biol Interact 98: 1-13.
23. Carmen Zafra-Polo M, Figadere B, Gallardo T, Tormo J, Cortes D, (1998) Natural acetogenins from annonaceae, synthesis and mechanisms of action. Phytochemistry 48: 1087-1117.
24. Nakanishi S, Abe M, Yamamoto S, Murai M, Miyoshi H, (2011) Bis-THF motif of acetogenin binds to the third matrix-side loop of ND1 subunit in mitochondrial NADH-ubiquinone oxidoreductase. Biochim Biophys Acta 1807: 1170-1176.
25. Jiang S, Li Y, Chen XG, Hu TS, Wu YL, et al. (2004) Parallel Fragment Assembly Strategy Towards Multiple-Ether Mimicry of Anticancer Annonaceous Acetogenins. Angew Chem Intl Ed 43: 329-334.
26. Xiao Q, Liu Y, Qiu Y, Zhou G, Mao C, et al. (2010) Potent Antitumor Mimetics of Annonaceous Acetogenins Embedded with an Aromatic Moiety in the Left Hydrocarbon Chain Part. J Med Chem 54: 525-533.
27. Xiao Q, Liu Y, Qiu Y, Yao Z, Zhou G, et al. (2011) Design, synthesis of symmetrical bivalent mimetics of annonaceous acetogenins and their cytotoxicities. Bioorgan Med Chemi Lett 21: 3613-3615.
28. Yao ZJ, Wu YL, (1995) Synthetic Studies toward Mono-THF Annonaceous Acetogenins: A Diastereoselective and Convergent Approach to Corossolone and (10RS)-Corossoline. J Org Chem 60: 1170-1176.
29. Ma L, Wen ZS, Liu Z, Hu Z, Ma J, et al. (2011) Overexpression and Small Molecule-Triggered Downregulation of CIP2A in Lung Cancer. PLoS ONE 6: e20159.
30. Yu XJ, Han QB, Wen ZS, Ma L, Gao J, et al. (2012) Gambogenic acid induces G1 arrest via GSK3b-dependent cyclin D1 degradation and triggers autophagy in lung cancer cells. Cancer Letters 322: 185-194.
31. Liu Y, Chen XQ, Liang HX, Zhang FX, Zhang B, et al. (2011) Small Compound 6-O-Angeloylplenolin Induces Mitotic Arrest and Exhibits Therapeutic Potentials in Multiple Myeloma. PLoS ONE 6: e21930.
32. Hu Z, Pan XF, Wu FQ, Ma LY, Liu DP, et al. (2009) Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia. PLoS ONE 4: e6257.
33. Chou TC, Talalay P, (1981) Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 115: 207-216.
34. Zhou GB, Kang H, Wang L, Gao L, Liu P, et al. (2007) Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood 109: 3441-3450.
35. Fang HT, Zhang B, Pan XF, Gao L, Zhen T, et al. (2012) Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells. Proc Natl Acad Sci U S A 109: 2521-2526.
36. Liu HX, Huang GR, Zhang HM, Jiang S, Wu JR, et al. (2007) Cover Picture: A structure-activity guided strategy for fluorescent labeling of annonaceous acetogenin mimetics and their application in cell biology. ChemBioChem 8: 153.
37. Hardie DG, (2003) Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 144: 5179-5183.
38. Kang HT, Hwang ES, (2006) 2-Deoxyglucose: An anticancer and antiviral therapeutic, but not any more a low glucose mimetic. Life Sciences 78: 1392-1399.
39. Peng DJ, Wang J, Zhou JY, Wu GS, (2010) Role of the Akt/mTOR survival pathway in cisplastin resistance in ovarian cancer cells. Biochem Biophys Res Commun 394: 600-605.
40. Zafra-Polo MC, Gonzalez MC, Estornell E, Sahpaz S, Cortes D, (1996) Acetogenins from Annonaceae, inhibitors of mitochondrial complex I. Phytochemistry. 42: 253-271.
41. Jiang S, Liu ZH, Sheng G, Zeng BB, Cheng XG, et al. (2002) Mimicry of annonaceous acetogenins: enantioselective synthesis of a (4R)-hydroxy analogue having potent antitumor activity. J Org Chem 67: 3404-3408.
42. Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, et al. (2010) Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 70: 2465-2475.
43. Pelicano H, Martin DS, Xu RH, Huang P, (2006) Glycolysis inhibition for anticancer treatment. Oncogene 25: 4633-4646.
44. Gogvadze V, Orrenius S, Zhivotovsky B, (2008) Mitochondria in cancer cells: what is so special about them? Trends in Cell Biology 18: 165-173.
45. Fath MA, Diers AR, Ykin-Burns N, Simons AL, Hua L, et al. (2009) Mitochondrial electron transport chain blockers enhance 2-deoxy-D-glucose induced oxidative stress and cell killing in human colon carcinoma cells. Cancer Biol Ther 8: 1228-1236.
46. Neuzil J, Dyason J, Freeman R, Dong LF, Prochazka L, et al. (2007) Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II. J Bioenerg Biomembr 39: 65-72.
47. Inoki K, Kim J, Guan KL, (2011) AMPK and mTOR in Cellular Energy Homeostasis and Drug Targets. Ann Rev Pharm Toxicol 52: 381-400.